XML 43 R28.htm IDEA: XBRL DOCUMENT
v3.21.1

BUSINESS ACQUISITIONS (Tables) | 12 Months Ended
--- | ---
Mar. 27, 2021
Schedule of Pro Forma Information | The results of acquired businesses are included in Transcat’s consolidated operating results as of the dates the businesses were acquired. The following unaudited pro forma information presents the Company’s results of operations as if the acquisitions of pipettes.com and BioTek had occurred at the beginning of fiscal year 2020. The pro forma results do not purport to represent what the Company’s results of operations actually would have been if the transactions had occurred at the beginning of the period presented or what the Company’s operating results will be in future periods. 58 Table of Contents
|  | (Unaudited) |
|  | Fiscal Years Ended |
|  | March 27, |  |  | March 28, |
|  | 2021 |  |  | 2020 |
Total Revenue |  | $ | 174,883 |  |  | $ | 182,459 |
Net Income |  | $ | 8,051 |  |  | $ | 9,017 |
Basic Earnings Per Share |  | $ | 1.08 |  |  | $ | 1.23 |
Diluted Earnings Per Share |  | $ | 1.07 |  |  | $ | 1.20 |
BioTek Services, Inc. [Member] |
Schedule of Purchase Price Allocation | The total purchase price paid for the assets of BioTek was approximately $3.5 million. $0.4 million of the purchase price has been put into escrow as a holdback for indemnification claims, if any. The following is a summary of the purchase price allocation, in the aggregate, to the fair value, based on Level 3 inputs, of BioTek’s assets and liabilities acquired during the period presented:
|  | FY 2021 |
Goodwill |  | $ | 1,063 |
Intangible Assets – Customer Base & Contracts |  |  | 1,930 |
Intangible Assets – Covenant Not to Compete |  |  | 100 |
|  |  | 3,093 |
Plus: Current Assets |  |  | 406 |
Non-Current Assets |  |  | 8 |
Total Purchase Price |  | $ | 3,507 |
TTE Laboratories, Inc. [Member] |
Schedule of Purchase Price Allocation | The total purchase price paid for the assets of pipettes.com was approximately $12.2 million. $1.2 million of the purchase price has been put into escrow as a holdback for indemnification claims, if any. The following is a summary of the purchase price allocation, in the aggregate, to the fair value, based on Level 3 inputs, of pipettes.com assets and liabilities acquired during the period presented.
|  | FY 2021 |
Goodwill |  | $ | 6,795 |
Intangible Assets – Customer Base & Contracts |  |  | 4,410 |
Intangible Assets – Covenant Not to Compete |  |  | 120 |
|  |  | 11,325 |
Plus: Current Assets |  |  | 884 |
Non-Current Assets |  |  | 261 |
Less: Current Liabilities |  |  | (239 | )
Total Purchase Price |  | $ | 12,231 |

X
- Definition Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(3) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionProFormaInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472 + Details
Name: | us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=trns_BioTekServicesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=trns_TTELaboratoriesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |